Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the firm behind them -- so individuals can make better investing decisions.

In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 145,000 members, many of whom demonstrate better investing insight than published analysts do.

After Amylin Pharmaceuticals (NASDAQ:AMLN) held no better than a three-star ranking for most of the past year, enough top-performing CAPS members have turned bullish on the company recently to upgrade it up to four stars. A total of 403 members have given their opinion on Amylin Pharmaceuticals, with many of them offering analysis explaining the recent optimism.

Amylin and partner Eli Lilly (NYSE:LLY) are up against competitors like Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in a market to treat diabetes, a disease that affects nearly 8% of the U.S. population. Amylin has reached several key milestones with its diabetes and obesity drugs lately that has more CAPS members feeling bullish. Its recent U.S. approval for its diabetes drug Byetta as a stand-alone drug could open up its reach to three or four times the 1 million patients who it has already treated, and investors like its chances for approval of its once-weekly version using technology developed by Alkermes.

Diabetes is highly correlated with obesity, and a deal with Japanese company Takeda Pharmaceutical to develop Amylin's obesity compounds could give Amylin a huge boost in the obesity treatment market. Amylin pocketed $75 million up front, with the possibility for $1 billion or more for hitting certain milestones. CAPS members like the huge potential market for obesity drugs, as the World Health Organization estimates a continuing rise in the number of obese adults. Prescription drugs account for less than 1% of the massive weight-loss products market. Roche and Abbott Laboratories (NYSE:ABT) have top-selling obesity drugs, while others like Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) are working on their own.  

Do you think Amylin Pharmaceuticals deserves its raised status? Add your thoughts in the comments box below on this page, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.

The Motley Fool Stock Advisor service looks for companies with strong management poised to beat the market over the long haul. To see all the stocks that have helped Tom and David Gardner beat the market by 51 points on average, take a free 30-day trial.